Cytarabine, Depocyte(cytarabine)
Cytarabine, DepoCyte, Vyxeos (cytarabine) is a small molecule pharmaceutical. Cytarabine was first approved as Cytarabine on 1982-01-01. It is used to treat leukemia, lymphoma, and meningeal neoplasms in the USA. It has been approved in Europe to treat meningeal neoplasms and myeloid leukemia acute.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cytarabine (discontinued: Cytarabine, Cytosar-u, Depocyt)
CombinationsVyxeos
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cytarabine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DEPOCYT | Pacira BioSciences | N-021041 DISCN | 1999-04-01 | 1 products, RLD |
| CYTARABINE | Teva | N-016793 DISCN | 1982-01-01 | 4 products, RLD |
Hide discontinued
Cytarabine
+
Daunorubicin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VYXEOS | Jazz Pharmaceuticals | N-209401 RX | 2017-08-03 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| byun rak | unapproved drug other | 2019-03-21 |
| cytarabine | ANDA | 2025-04-07 |
| vyxeos | New Drug Application | 2025-07-01 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CYTARABINE / DAUNORUBICIN, VYXEOS, CELATOR PHARMS | |||
| 2028-03-30 | ODE-350 | ||
| 2024-08-03 | ODE-287 | ||
| 2024-03-30 | NPP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Cytarabine / Daunorubicin, Vyxeos, Celator Pharms | |||
| 10028912 | 2032-10-15 | DP | U-3149, U-3150 |
| 10166184 | 2032-10-15 | DP | U-3149 |
| 10835492 | 2032-10-15 | U-3150 | |
| 8092828 | 2029-04-01 | U-3147 | |
| 8022279 | 2027-09-14 | DP | U-3147 |
| 7850990 | 2027-01-23 | DP | U-3147 |
| 9271931 | 2027-01-23 | DP | |
| 8518437 | 2026-06-07 | DP | |
| 8431806 | 2025-04-22 | DP | U-3147 |
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01B: Antimetabolites
— L01BC: Pyrimidine analogues, antineoplastic antimetabolites
— L01BC01: Cytarabine
— L01X: Other antineoplastic agents in atc
— L01XY: Combinations of antineoplastic agents
— L01XY01: Cytarabine and daunorubicin
Clinical
Clinical Trials
1704 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 11 | 14 | 3 | — | — | 24 |
| Leukemia | D007938 | — | C95 | 9 | 11 | 2 | — | — | 20 |
| Myeloid leukemia | D007951 | — | C92 | 9 | 9 | 3 | — | — | 18 |
| Myelodysplastic syndromes | D009190 | — | D46 | 4 | 4 | 1 | — | — | 8 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | 5 | — | — | — | 6 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 2 | 3 | — | — | — | 5 |
| Preleukemia | D011289 | — | — | 2 | 1 | — | — | — | 3 |
| Eyelid neoplasms | D005142 | EFO_1000934 | — | — | 3 | — | — | — | 3 |
| Hematologic neoplasms | D019337 | — | — | 2 | 1 | — | — | — | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | 1 | 2 |
| Lymphoid leukemia | D007945 | — | C91 | — | 2 | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 1 | — | — | — | 2 |
| Lymphoma | D008223 | — | C85.9 | 1 | 1 | — | — | — | 2 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 2 | — | — | — | — | 2 |
| Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | — | 1 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | — | — | — | — | 1 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 1 | — | — | — | — | 1 |
| Burkitt lymphoma | D002051 | — | C83.7 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cytarabine |
| INN | cytarabine |
| Description | Cytarabine is a pyrimidine nucleoside in which cytosine is attached to D-arabinofuranose via a beta-N(1)-glycosidic bond. Used mainly in the treatment of leukaemia, especially acute non-lymphoblastic leukaemia, cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It also has antiviral and immunosuppressant properties. It has a role as an antineoplastic agent, an antimetabolite, an antiviral agent and an immunosuppressive agent. It is a beta-D-arabinoside, a pyrimidine nucleoside and a monosaccharide derivative. It is functionally related to a cytosine. |
| Classification | Small molecule |
| Drug class | antineoplastics (arabinofuranosyl derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1 |
Identifiers
| PDB | — |
| CAS-ID | 147-94-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL803 |
| ChEBI ID | 28680 |
| PubChem CID | 6253 |
| DrugBank | DB00987 |
| UNII ID | 04079A1RDZ (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Depocyte – Pacira BioSciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Vyxeos – Jazz Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Cytarabine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 45,537 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cytarabine, Vyxeos
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
58,572 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use